Cargando…
The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis
PURPOSE: A retrospective analysis of real-world data was performed to assess the epidemiology and economic burden of multiple sclerosis (MS), relapsing-remitting MS (RRMS), and secondary-progressive MS (SPMS) in Italy. PATIENTS AND METHODS: An observational study on administrative databases from a s...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648183/ https://www.ncbi.nlm.nih.gov/pubmed/36387930 http://dx.doi.org/10.2147/CLEP.S376005 |
_version_ | 1784827522477719552 |
---|---|
author | Perrone, Valentina Veronesi, Chiara Giacomini, Elisa Citraro, Rita Dell’Orco, Stefania Lena, Fabio Paciello, Arrigo Resta, Anna Maria Nica, Mihaela Ritrovato, Daniela Degli Esposti, Luca |
author_facet | Perrone, Valentina Veronesi, Chiara Giacomini, Elisa Citraro, Rita Dell’Orco, Stefania Lena, Fabio Paciello, Arrigo Resta, Anna Maria Nica, Mihaela Ritrovato, Daniela Degli Esposti, Luca |
author_sort | Perrone, Valentina |
collection | PubMed |
description | PURPOSE: A retrospective analysis of real-world data was performed to assess the epidemiology and economic burden of multiple sclerosis (MS), relapsing-remitting MS (RRMS), and secondary-progressive MS (SPMS) in Italy. PATIENTS AND METHODS: An observational study on administrative databases from a sample of Italian entities was carried-out. Between 01/2010–12/2017, patients with ≥1 MS diagnosis code (ICD-9-CM:340 and/or exemption code:046) and/or ≥1 disease-modifying therapies (DMTs) prescription, were included. Among MS-cohort, SPMS patients were identified by ≥2 hospitalizations or by ≥2 drug prescriptions related to MS progression. MS patients not fulfilling SPMS criteria were included as RRMS. Mean annual healthcare costs were reported during follow-up and stratified by DMT treatment/untreatment. RESULTS: Overall, 9543 MS patients were included; 8397 with RRMS and 1146 with SPMS. Estimated prevalence of MS was 141.6/100,000 inhabitants (RRMS 124.4/100,000 and SPMS 17.2/100,000). Mean annual cost for untreated and treated patient was respectively: €3638 and €11796 (MS-cohort), €3183 and €11486 (RRMS-cohort), €6317 and €15511 (SPMS-cohort). The first-line DMT treatment duration averaged 27.4 ± 22.8 months; the mean cost was 19004€ for the whole period. The second-line DMT treatment lasted on average 31.1 ± 24.5 months; the mean cost was 47293€ for the whole period. CONCLUSION: This study provided insights into the MS epidemiology in Italy and its economic burden. Healthcare costs associated with MS management were mainly driven by DMTs expenditure. A trend of higher healthcare-resource consumption was observed among SPMS-cohort. |
format | Online Article Text |
id | pubmed-9648183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-96481832022-11-15 The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis Perrone, Valentina Veronesi, Chiara Giacomini, Elisa Citraro, Rita Dell’Orco, Stefania Lena, Fabio Paciello, Arrigo Resta, Anna Maria Nica, Mihaela Ritrovato, Daniela Degli Esposti, Luca Clin Epidemiol Original Research PURPOSE: A retrospective analysis of real-world data was performed to assess the epidemiology and economic burden of multiple sclerosis (MS), relapsing-remitting MS (RRMS), and secondary-progressive MS (SPMS) in Italy. PATIENTS AND METHODS: An observational study on administrative databases from a sample of Italian entities was carried-out. Between 01/2010–12/2017, patients with ≥1 MS diagnosis code (ICD-9-CM:340 and/or exemption code:046) and/or ≥1 disease-modifying therapies (DMTs) prescription, were included. Among MS-cohort, SPMS patients were identified by ≥2 hospitalizations or by ≥2 drug prescriptions related to MS progression. MS patients not fulfilling SPMS criteria were included as RRMS. Mean annual healthcare costs were reported during follow-up and stratified by DMT treatment/untreatment. RESULTS: Overall, 9543 MS patients were included; 8397 with RRMS and 1146 with SPMS. Estimated prevalence of MS was 141.6/100,000 inhabitants (RRMS 124.4/100,000 and SPMS 17.2/100,000). Mean annual cost for untreated and treated patient was respectively: €3638 and €11796 (MS-cohort), €3183 and €11486 (RRMS-cohort), €6317 and €15511 (SPMS-cohort). The first-line DMT treatment duration averaged 27.4 ± 22.8 months; the mean cost was 19004€ for the whole period. The second-line DMT treatment lasted on average 31.1 ± 24.5 months; the mean cost was 47293€ for the whole period. CONCLUSION: This study provided insights into the MS epidemiology in Italy and its economic burden. Healthcare costs associated with MS management were mainly driven by DMTs expenditure. A trend of higher healthcare-resource consumption was observed among SPMS-cohort. Dove 2022-11-06 /pmc/articles/PMC9648183/ /pubmed/36387930 http://dx.doi.org/10.2147/CLEP.S376005 Text en © 2022 Perrone et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Perrone, Valentina Veronesi, Chiara Giacomini, Elisa Citraro, Rita Dell’Orco, Stefania Lena, Fabio Paciello, Arrigo Resta, Anna Maria Nica, Mihaela Ritrovato, Daniela Degli Esposti, Luca The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis |
title | The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis |
title_full | The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis |
title_fullStr | The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis |
title_full_unstemmed | The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis |
title_short | The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis |
title_sort | epidemiology, treatment patterns and economic burden of different phenotypes of multiple sclerosis in italy: relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648183/ https://www.ncbi.nlm.nih.gov/pubmed/36387930 http://dx.doi.org/10.2147/CLEP.S376005 |
work_keys_str_mv | AT perronevalentina theepidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT veronesichiara theepidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT giacominielisa theepidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT citrarorita theepidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT dellorcostefania theepidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT lenafabio theepidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT pacielloarrigo theepidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT restaannamaria theepidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT nicamihaela theepidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT ritrovatodaniela theepidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT degliespostiluca theepidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT perronevalentina epidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT veronesichiara epidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT giacominielisa epidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT citrarorita epidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT dellorcostefania epidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT lenafabio epidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT pacielloarrigo epidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT restaannamaria epidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT nicamihaela epidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT ritrovatodaniela epidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis AT degliespostiluca epidemiologytreatmentpatternsandeconomicburdenofdifferentphenotypesofmultiplesclerosisinitalyrelapsingremittingmultiplesclerosisandsecondaryprogressivemultiplesclerosis |